关于循环CEACAM1在胰岛素清除和疾病进展方面的见解:来自葡萄牙PREVADIAB2研究的证据
Rita S Patarrão1, Maria João Meneses1, Hilda E Ghadieh2,3
1iNOVA4Health, NOVA Medical School, Faculdade de Ciências Médicas, NMS, FCM, Universidade NOVA de Lisboa, Lisbon, Portugal.
European journal of clinical investigation
|December 15, 2024
概括
循环中的CEACAM1水平随着2型糖尿病和肥胖症的恶化而下降,反映出胰岛素清除率降低. 较低的CEACAM1表明胰岛素代谢受损,并表明其作为代谢疾病进展的生物标志物的潜力.
科学领域:
- 内分泌学 在内分泌学.
- 代谢疾病 代谢疾病
- 生物标志物发现发现
背景情况:
- 2型糖尿病 (T2DM) 和肥胖症涉及胰岛素代谢和作用的改变.
- 肝脏胰岛素清除减少有助于高胰岛素血症和胰岛素抵抗.
- 肝细胞中CEACAM1损失与胰岛素清除率降低有关.
研究的目的:
- 调查循环中的CEACAM1水平是否反映了胰岛素代谢和耐药性的损害.
- 分析PREVADIAB2队列中关于代谢健康的CEACAM1水平.
主要方法:
- 从PREVADIAB2队列中的1019人使用OGTT.被评估是否患有糖尿病.
- 通过ELISA测量了循环中的CEACAM1水平.
- 阶层分类分析了胰岛素代谢指数和CEACAM1水平.
主要成果:
- 胰岛素耐药性,HOMA-IR和肝肥胖症随着疾病的严重程度而增加.
- 胰岛素分泌量增加,清除量下降,以及糖尿病前期和T2DM中CEACAM1的下降.
- 胰岛素清除与CEACAM1正相关,特别是在正常血糖和较低肥胖症的个体中.
结论:
- 渐进的胰岛素耐药性和高胰岛素血症与BMI升高,肝硬化和CEACAM1.1下降相关.
- 降低胰岛素清除与循环CEACAM1水平的降低有关.
- 循环中的CEACAM1显示出作为代谢性疾病进展的生物标志物的潜力.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
5.0K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.0K
Type I Diabetes II: Pathophysiology
122
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular...
122
Type I Diabetes III: Clinical Manifestations
53
Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the...
53
Type II Diabetes II: Pathophysiology
45
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
45
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
32
Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated...
32
Chronic Pancreatitis II: Pathophysiology
36
Chronic pancreatitis is a progressive and irreversible inflammation of the pancreas, most often caused by long-term alcohol abuse, but it can also be related to ductal obstruction, smoking, or genetic factors.Chronic pancreatitis occurs when the pancreas is repeatedly exposed to harmful agents like alcohol, smoking, ductal obstruction, or genetic predisposition. These factors lead to the release of toxic metabolites and inflammatory cytokines, sustaining chronic inflammation in the pancreatic...
36


